Sanguigni Valerio, Ferro Domenico, Pignatelli Pasquale, Del Ben Maria, Nadia Tini, Saliola Mirella, Sorge Roberto, Violi Francesco
Department of Internal Medicine, University of Rome "Tor Vergata," Rome, Italy.
J Am Coll Cardiol. 2005 Jan 4;45(1):35-42. doi: 10.1016/j.jacc.2004.09.047.
We tested the hypothesis that CD40 ligand (CD40L) induces a prothrombotic state by enhancing oxidative stress.
Patients with hypercholesterolemia show an ongoing prothrombotic state, but the underlying mechanism is still unclear.
Circulating levels of the soluble form of CD40L (sCD40L), prothrombin fragment (F1+2, a marker of thrombin generation), and 8-hydroxy-2'-deoxyguanosine (8-OHdG, a marker of oxidative stress) were measured in 40 patients with hypercholesterolemia and in 20 age- and gender-matched healthy subjects.
Patients with hypercholesterolemia showed significantly higher levels of sCD40L (p <0.005), 8-OHdG (p <0.005), and prothrombin F1+2 (p <0.005), as compared with control subjects. Soluble CD40L significantly correlated with 8-OHdG (r=0.85, p <0.0001) and prothrombin F1+2 (r=0.83, p <0.0001); a significant correlation between 8-OHdG and prothrombin F1+2 was also observed (r=0.64, p <0.0001). An in vitro study demonstrated that CD40L-stimulated monocytes from patients with hypercholesterolemia expressed more tissue factor (TF) and prothrombin F1+2 than monocytes from controls; co-incubation of monocytes with either an inhibitor of NADPH oxidase or an inhibitor of phosphatidylinositol-3-kinase significantly reduced CD40L-mediated clotting activation. A marked inhibition of CD40L-mediated clotting activation was also observed in two male patients with hereditary deficiency of gp91 phox, the central core of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase. Finally, we demonstrated that CD40L-mediated clotting activation was significantly inhibited by vitamin C, a known antioxidant.
This study indicates that in patients with hypercholesterolemia, CD40L over-expresses TF and increases the thrombin generation rate by an oxidative stress-mediated mechanism that requires the activation of NADPH oxidase.
我们检验了如下假设,即CD40配体(CD40L)通过增强氧化应激诱导促血栓形成状态。
高胆固醇血症患者呈现持续的促血栓形成状态,但其潜在机制仍不清楚。
检测了40例高胆固醇血症患者及20例年龄和性别匹配的健康受试者循环中可溶性CD40L(sCD40L)、凝血酶原片段(F1+2,凝血酶生成的标志物)和8-羟基-2'-脱氧鸟苷(8-OHdG,氧化应激的标志物)的水平。
与对照组相比,高胆固醇血症患者的sCD40L(p<0.005)、8-OHdG(p<0.005)和凝血酶原F1+2(p<0.005)水平显著更高。可溶性CD40L与8-OHdG(r=0.85,p<0.0001)和凝血酶原F1+2(r=0.83,p<0.0001)显著相关;8-OHdG与凝血酶原F1+2之间也观察到显著相关性(r=0.64,p<0.0001)。一项体外研究表明,与对照组的单核细胞相比,CD40L刺激的高胆固醇血症患者的单核细胞表达更多组织因子(TF)和凝血酶原F1+2;单核细胞与NADPH氧化酶抑制剂或磷脂酰肌醇-3-激酶抑制剂共同孵育可显著降低CD40L介导的凝血激活。在两名遗传性gp91 phox缺乏的男性患者中也观察到CD40L介导的凝血激活受到显著抑制,gp91 phox是烟酰胺腺嘌呤二核苷酸磷酸(NADPH)氧化酶的核心。最后,我们证明维生素C(一种已知的抗氧化剂)可显著抑制CD40L介导的凝血激活。
本研究表明,在高胆固醇血症患者中,CD40L通过一种需要NADPH氧化酶激活的氧化应激介导机制,使TF过度表达并增加凝血酶生成率。